Not sure how much longer you "nay" sayers are going to
Not sure how much longer you "nay" sayers are going to stick around as this company and its SHARE PRICE sky rocket but in my world if a lender/bank can forecast with some degree of certainty that theres ample opportunity to make several BILLION DOLLARS in revenue - I would assume the "Branch Manager" will sign off on the loan.
More good news coming!!!
All you longs out there take a deep breath and check back on this stock in less then 2 weeks...
For those who haven't seized the day value is disappearing but we still have a long way to go >>>>>>>$1.00...and beyond.
GLTA!!! Except a couple of small minded shorts...
Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
So here’s the scoop: Rate just teamed up with Betterment on February 17, 2026, offering some pretty slick mortgage incentives for those sitting on at least $100K in their investment accounts. But let’s dig into the nitty-gritty before you start dreaming of that low-rate home loan. Betterment's Strategy: Solid Gains or Hype? The partnership aims to deliver discounted...
Continue Reading
Morgan Stanley Highlights UK Water Sector Improvements Investment risks surrounding listed UK water companies have significantly decreased following a key regulatory decision concerning water bill increases in England and Wales. According to analysts from Morgan Stanley, this development has created a more favorable landscape for investors in the sector. Key Insights From...
Continue Reading
SiLC Technologies Introduces Eyeonic Trace Laser Line Scanner SiLC Technologies, a leader in the development of advanced integrated FMCW LiDAR solutions, recently announced an exciting new product: the Eyeonic Trace Laser Line Scanner. This state-of-the-art Class 1 Laser Line Scanner is engineered to achieve precise measurements of objects from distances of up to 10...
Continue Reading
Accord BioPharma Announces FDA Approval for HERCESSI™ Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has achieved a major milestone in cancer treatment with the FDA's approval of a new 420mg strength of HERCESSI™ (trastuzumab-strf). This biosimilar to Herceptin (trastuzumab) targets different types of HER2-overexpressing cancers, such as...
Continue Reading
What’s Driving Oklo Inc’s Stock Surge? Oklo Inc (NYSE: OKLO) is making waves in the stock market as its shares witness impressive growth. Over the past month, the company has experienced a remarkable rally of approximately 60%. Investors are keen to learn about the driving forces behind this upward trend. Recent Positive Developments This recent surge can primarily be...
Continue Reading